6FN Stock Chart & Stats
€0.06
>-€0.01(-25.00%)
At close: 4:00 PM EST
€0.06
>-€0.01(-25.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)8.58K
Market Cap
€19.29M
Enterprise Value€216.06
Total Cash (Recent Filing)€260.00K
Total Debt (Recent Filing)€9.70M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding245,976,150
10 Day Avg. Volume650
30 Day Avg. Volume8,579
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€2.22M
Bulls Say, Bears Say
Bulls Say
Platform & Licensing PotentialKlaria’s buccal thin-film drug‑delivery platform is a durable strategic asset: it targets formulation and delivery advantages that are attractive to larger pharma partners. A platform model supports recurring licensing/milestone revenue without heavy commercial infrastructure, enabling scalable partner monetization over months to years.
High Gross Margin EpisodesReported episodes of very high gross margins indicate attractive unit economics for film-based products. If replicated in partnered or commercial programs, these margins support compelling royalty and licensing economics, helping sustain partner interest and improving long-term returns on development investments.
Lean, Partnership-Focused Operating ModelA very small headcount reflects a lean R&D and business development model oriented toward partnering rather than full-scale commercialization. Lower fixed costs can extend runway per financing round and align incentives with out‑licensing, making the business model more capital efficient and resilient across funding cycles.
Bears Say
Severe Revenue DeclineA near-total revenue collapse is a lasting fundamental concern: it erodes bargaining power with partners, suggests lost or discontinued commercial streams, and reduces observable proof points for the platform. Over 2–6 months this materially weakens cash runway and heightens execution risk for development programs.
Negative Shareholders' EquityNegative equity is a structural red flag that constrains access to traditional financing and increases the likelihood of equity dilution or distressed financing. It signals cumulative losses that impair capital structure flexibility, making sustained R&D investment and partner confidence more difficult over the medium term.
Persistent Operating Cash BurnChronic negative operating cash flow indicates the company cannot self-fund development and relies on external capital. This dependency increases execution risk, potential dilution, and the chance of program delays if financing terms deteriorate — a durable constraint on advancing pipeline programs.
6FN FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was €0.03 and its highest was €0.12 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is €19.29M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is Aug 27, 2026 which is in 20 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on May 29, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in DE:6FN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.